Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients

Barroso-Sousa, Romualdo; Munhoz, Rodrigo R.; Mak, Milena P.; Fonseca, Leonardo G.; Fede, Angelo B. S.; Linck, Rudinei Diogo Marques; Coelho, Clovis R.; Moniz, Camila M. V.; Souza, Ciro E.; Dzik, Carlos.
Int. braz. j. urol ; 40(6): 835-841, Nov-Dec/2014. tab, graf
Artículo en Inglés | LILACS | ID: lil-735985

Documentos relacionados

  1. Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma.
  2. Heavy Metal Enlightens Tumor Immunity.
  3. Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma.
  4. Cytoreductive surgery, systemic treatment, genetic evaluation, and patient perspective in a young adult with metastatic renal cell carcinoma.
  5. Papillary Renal Cell Carcinoma: Evolving Classification by Combined Morphologic and Molecular Means.
  6. Molecular differences in renal cell carcinoma between males and females.
  7. Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome.
  8. Prognostic Significance of Tumor-Associated Inflammation in Renal Cell Carcinoma.
  9. CircPTEN suppresses human clear cell renal carcinoma progression and resistance to mTOR inhibitors by targeting epigenetic modification.
  10. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.